ArticleFrontiers in oncology2023

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.

Kathrin Olschok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.